Exploiting synthetic lethality to personalize treatment of leukemia

Impact: use of Gene Expression and Mutation Analysis (GEMA) to direct effective leukemia treatment



Our findings:

- Patient-specific defects in DNA-repair lead to distinct therapeutic vulnerabilities

Implications:

- Molecular analysis of leukemia mutations - mediated modulation of DNA repair activities enables patient-oriented synthetic lethality therapy
- Potential for improved therapeutic efficacy and less toxicity in an extremely challenging disease

Tomasz Skorski, Professor and Director, Fels Cancer Institute for Personalized Medicine

Recent publications:

Blood 2017; JCI 2017; Blood 2018; Cell Rep. 2018, 2020;

Supported by NCI R01s CA247707, CA186238, CA244044, CA237286, CA244179, CA216813, R41CA239983, Leukemia and Lymphoma Society TRP 6565-19 and TRP 6828-21